The Australian and New Zealand College of Anaesthetists (ANZCA) has more than 200 accredited training sites in Australia, New Zealand, Hong Kong, Malaysia and Singapore, many of which participate in ANZCA Clinical Trials Network (CTN)-endorsed clinical trials. We undertook a survey of accredited sites to determine research capability, activity and potential. With ethics committee approval an electronic survey was distributed to accredited sites in July 2015. Of 207 accredited sites, 167 were sent the questionnaire (after eliminating ineligible sites) and 128 responded. Response rates for Australia, New Zealand, Hong Kong, Malaysia and Singapore were 100%, 100%, 35%, 25% and 75% respectively. Forty-four (34%) of 128 responding sites had a head of research; 101 (80%) of 126 responding sites were active in research; 42 (33%) of 126 responding sites had no publications since January 2011 and 15 (12%) had >50 publications; 95 (76%) of 125 responding sites had at least one specialist anaesthetist engaged in research (median = 4 [range 1-25]); and 45 (36%) of 125 responding sites had at least one research coordinator (median = 2 [range 1-15]). Fifty-eight (28%) of the 207 accredited sites were identified as participating in recent ANZCA CTN-endorsed clinical trials. Research capability and activity were higher in these sites. This survey has identified a strong base upon which to expand clinical trial activity, and regions, sectors, investigators and research coordinators who may benefit from additional support.
Introduction
Medical research is fundamental to improving the health of people and communities 1 . The aim of the Australian and New Zealand College of Anaesthetists (ANZCA) Clinical Trials Network (CTN) is to deliver high quality trial evidence that translates into safe and effective practice in anaesthesia, and perioperative and pain medicine 2 . In the last twenty years more than 30,000 patients have been randomised to ANZCA CTN-endorsed clinical trials, including MASTER 3 , B-Aware 4 , ENIGMA-I 5 , ENIGMA-II 6 , POISE-I 7 , POISE-II 8, 9 , and ATACAS 10 . In order to build on this success, the CTN has prioritised enhancing existing research capability and building capability among new sites, investigators and research coordinators.
ANZCA has more than 200 accredited training sites, including public and private hospitals, simulation centres and retrieval services, in Australia, New Zealand, Hong Kong, Malaysia and Singapore 11 . All sites must support the research learning objectives in the ANZCA training curriculum, and many are actively engaged in ANZCA CTN-endorsed clinical trials. This network therefore potentially provides a rich source of new research sites. However, no data are available about research capability, activity and potential across the whole ANZCA training network.
The CTN Executive therefore undertook a survey of ANZCA accredited training sites. The objectives of the survey were to: 1) document the current state of research capability, 2) identify research leaders and emerging research leaders to engage and further support, 3) identify research coordinators, their full-time equivalent (FTE) workplace commitment and how they are funded, and 4) describe the training sites involved in ANZCA CTN-endorsed clinical trials.
Methods
This survey was overseen by a working group of the ANZCA CTN Executive. The survey was approved by the Melbourne Health Office for Research under its quality assurance and negligible risk research process (QA2015106 dated 15 July 2015). Consent was implied if the recipient completed the survey.
An electronic survey was designed in LimeSurvey (Carsten Schmitz, Germany). The survey consisted of 17 questions capturing department information, research areas and achievement, staffing and funding for each site (Appendix 1). The survey was piloted among CTN Executive members and research coordinators before dissemination.
The geographical locations of Australian accredited training sites were classified using Australian Standard Geographical Classification Remoteness Areas 12 , to assess capability and potential outside metropolitan areas. Similarly hospitals were identified as public or private from College records, so that we could assess capability and potential in private sector training sites. A research leader was defined as an investigator with all of the following characteristics Research Grant Council (HKRGC), or equivalent, grant. An emerging research leader was defined as an investigator with at least two of these characteristics. We defined a research coordinator as a staff member with an employment classification and/or position description that designates research responsibilities. A list of accredited training sites and heads of department was sourced from the ANZCA website 11 . Forty sites that were not primary training sites were excluded a priori leaving 167 eligible sites ( Figure 1 ). The invitation, which included a unique link to the webbased survey, was emailed to each head of department in July 2015. An email reminder was sent six weeks later to those who had not completed the survey. Follow-up phone calls were made between October and November 2015 to heads of department who had not responded. A list of sites participating in recent ANZCA CTN-endorsed clinical trials was sourced from the CTN contacts database.
The dataset was exported to Microsoft Excel for analysis. Incomplete responses were followed up by phone. Data were summarised using number (%) or median (range). Categorical data were compared using chi-squared tests. Stata 14.1 was used for statistical analyses and a P value <0.05 was considered statistically significant.
Results
Twenty-four heads of department completed one survey for a group of sites (i.e. a primary site with one or more satellites) leaving 143 sites from the original 167 sites. Survey responses were received from 128 of these 143 sites (response rate = 90%) ( Figure 1 ). Of these, 123 (96%) were public hospitals and 5 (4%) were private hospitals. Response rates for Australia, New Zealand, Hong Kong, Malaysia and Singapore were 100%, 100%, 35%, 25% and 75% respectively. Some surveys remained incomplete despite follow-up (denominators of all responses indicated below).
Forty-four (34%) of 128 responding sites had a head of research. Thirty (68%) heads of research had, and four (9%) were obtaining, a research qualification, and 34 (77%) had a university affiliation. Thirty heads of research (68%) had published at least one research paper since 2011 and 26 (59%) had at least one funded grant application.
One hundred and one (80%) of 126 responding sites were active in research (multicentre trials = 79 [63%]; single centre clinical trials = 68 [54%]; commercially-sponsored trials = 3 [2%]; systematic reviews = 5 [4%]; basic science = 6 [5%]; audit = 32 [25%]). Forty-two (33%) of these sites had no publications since January 2011; 35 (28%) had 1-5 publications; 23 (18%) had 6-20 publications; 11 (9%) had 21-50 publications and 15 (12%) had >50 publications.
Ninety-five (76%) of 125 responding sites had at least one specialist anaesthetist engaged in research (median = 4 [range 1-25]); 34 (27%) had at least one researcher who was not a specialist anaesthetist (median = 2 [range 1-35]); of accredited sites in Remoteness Area 1 (major city), 13% of accredited sites in Remoteness Area 2 (inner regional), 29% of accredited sites in Remoteness Area 3 (outer regional) and none of the accredited sites in Remoteness Area 4 (remote) or 5 (very remote) were participating in ANZCA CTN-endorsed clinical trials. Data for Australian states and territories, and other countries is reported in Figure 2 . These differences were statistically significant (P=0.015).
Data for two of the 58 CTN participating sites were included in a response for a group of sites, and two CTN participating sites did not respond. Survey data therefore were available for 54 CTN participating sites (three of these participated in the recent past but not at present). The 54 CTN participating sites differed from non-participating sites in terms of research capability ( 
Discussion
This survey identified a strong base upon which to build clinical trial research capability among ANZCA accredited training sites. Of the 128 responding sites 34% had a head of research, 76% had specialist anaesthetists actively participating in research and 36% had at least one research coordinator. More than 50% of research coordinator FTE was funded by research grants. We identified at least one research leader at 18% of sites and at least one emerging leader at 46% of sites. Of the 207 accredited sites, 28% had recently participated in an ANZCA CTN-endorsed clinical trial. There was strong participation of sites accredited for longer durations of training (2-3 years), which is consistent with the requirements of the ANZCA training curriculum, caseload and resources in these hospitals, and sites in inner regional Australia and New Zealand. Research capability and activity was significantly higher at sites participating in ANZCA CTNendorsed clinical trials. The survey revealed 28 centres that were not participating in CTN activity, but were conducting single and/or multicentre trials. This represents a large proportion of current clinical trial activity in anaesthesia in ANZCA accredited sites taking place in parallel to that of the CTN. While this activity is clearly welcome, opportunities for improved research outcomes through exploitation of the resources of the CTN may be missed. This may be worthy of investigation in future surveys.
This report provides the first comprehensive profile of research capability across ANZCA accredited training sites.
A strength of our survey is its extremely high response rate (90%), particularly in Australia and New Zealand (both 100%), and few missing data. The survey was limited by its crosssectional nature and our inability to unravel the association between participation in ANZCA CTN-endorsed clinical trials and higher research capability. In addition we did not collect or correlate information about apparent research capability and actual recruitment to clinical trials. A further weakness may be our definition of a 'research leader', which was developed by us during our strategic planning process, and which may not be generalisable to other research collaborations or regions. The definition included a requirement to be a site chief investigator in an ANZCA CTN-endorsed clinical trial; this was also an outcome of the survey.
No other studies of research capability in anaesthesia training sites in our region or internationally have been published. A previous survey of intentions and barriers to research for Australian and New Zealand anaesthetists revealed a 29% participation rate in research among respondents and identified stronger participation in academic centres in metropolitan areas 13 . This is consistent with our results. If other groups contemplate such a study they should note that, in our region, anaesthesia research is mainly conducted by salaried employees of our public hospital systems, rather than by university-based academics or in private practice, and that funding for research coordinators is heavily based on extra-mural funding. They should also note our unique College-supported clinical trials network, which allows direct funding of network infrastructure by members and direct integration of clinical trial research into training and continuing professional development.
This survey revealed high existing research capability and great potential for improvement. We have identified regions (such as New South Wales), sectors (such as private hospitals and outer regional sites), sites (such as hospitals with <2 years accreditation) and investigators (such as emerging leaders and heads of research without research qualifications or publications) to mentor and support. This may include workshops for emerging leaders, business plans for research coordinators and methodology/statistics assistance for investigators. We have discovered a pool of training sites with research capability to engage in ANZCA CTN-endorsed clinical trials. Our critical dependence on peer-reviewed grant funding has been exposed, inspiring us to redouble efforts to secure hospital, commercial and philanthropic funding for our research coordinators and programs. In the latter effort we are greatly assisted by the ANZCA Research Foundation (http://www.anzca.edu.au/research/foundation).
The ANZCA CTN research capability survey has identified a strong base upon which to expand clinical trial activity, and regions, sectors, investigators and research coordinators who may benefit from additional support. The survey should be repeated to measure progress. 
